Search research articles
Contact Us
Filters
Showing results (191-200 of 223) with videos related to
Page
of 23
Sort By:
JCI Insight
|
February 1, 2017
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
Jan A Burger, Kelvin W Li, Michael J Keating, et al.
Cancer
|
August 27, 2015
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Farhad Ravandi, Susan M O'Brien, Jorge E Cortes, et al.
Blood
|
December 12, 2018
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A Burger, Mariela Sivina, Nitin Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Matthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.
Blood Advances
|
June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
Steven E Coutre, John C Byrd, Peter Hillmen, et al.
Leukemia
|
May 3, 2021
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL
Gerardo Ferrer, Byeongho Jung, Pui Yan Chiu, et al.
American Journal of Hematology
|
September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir, Jennifer R Brown, Susan O'Brien, et al.
British Journal of Haematology
|
October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
Farhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
Marina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Nature Communications
|
December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Dan A Landau, Clare Sun, Daniel Rosebrock, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 223) with videos related to
Sort By:
Page
of 23
JCI Insight
|
February 1, 2017
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
Jan A Burger, Kelvin W Li, Michael J Keating, et al.
Cancer
|
August 27, 2015
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Farhad Ravandi, Susan M O'Brien, Jorge E Cortes, et al.
Blood
|
December 12, 2018
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A Burger, Mariela Sivina, Nitin Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Matthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.
Blood Advances
|
June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
Steven E Coutre, John C Byrd, Peter Hillmen, et al.
Leukemia
|
May 3, 2021
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL
Gerardo Ferrer, Byeongho Jung, Pui Yan Chiu, et al.
American Journal of Hematology
|
September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir, Jennifer R Brown, Susan O'Brien, et al.
British Journal of Haematology
|
October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
Farhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2014
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
Marina Y Konopleva, Roland B Walter, Stefan H Faderl, et al.
Nature Communications
|
December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Dan A Landau, Clare Sun, Daniel Rosebrock, et al.
Page
of 23